Author:
Kahnert K.,Föhrenbach M.,Lucke T.,Alter P.,Trudzinski F. T.,Bals R.,Lutter J. I.,Timmermann H.,Söhler S.,Förderreuther S.,Nowak D.,Watz H.,Waschki B.,Behr J.,Welte T.,Vogelmeier C. F.,Jörres R. A.
Abstract
Abstract
Background
Peripheral neuropathy is a common comorbidity in COPD. We aimed to investigate associations between alterations commonly found in COPD and peripheral neuropathy, with particular emphasize on the distinction between direct and indirect effects.
Methods
We used visit 4 data of the COPD cohort COSYCONET, which included indicators of polyneuropathy (repeated tuning fork and monofilament testing), excluding patients with diabetes a/o increased HbA1c. These indicators were analysed for the association with COPD characteristics, including lung function, blood gases, 6-min walk distance (6-MWD), timed-up-and-go-test (TUG), exacerbation risk according to GOLD, C-reactive protein (CRP), and ankle-brachial index (ABI). Based on the results of conventional regression analyses adjusted for age, BMI, packyears and gender, we utilized structural equation modelling (SEM) to quantify the network of direct and indirect relationships between parameters.
Results
606 patients were eligible for analysis. The indices of polyneuropathy were highly correlated with each other and related to base excess (BE), ABI and TUG. ABI was linked to neuropathy and 6-MWD, exacerbations depended on FEV1, 6-MWD and CRP. The associations could be summarized into a SEM comprising polyneuropathy as a latent variable (PNP) with three measured indicator variables. Importantly, PNP was directly dependent on ABI and particularly on BE. When also including patients with diabetes and/or elevated values of HbA1c (n = 742) the SEM remained virtually the same.
Conclusion
We identified BE and ABI as major determinants of peripheral neuropathy in patients with COPD. All other associations, particularly those with lung function and physical capacity, were indirect. These findings underline the importance of alterations of the micromilieu in COPD, in particular the degree of metabolic compensation and vascular status.
Funder
Deutsche Zentrum für Lungenforschung
BMBF
AstraZeneca
Boehringer Ingelheim Pharma GmbH & Co. KG
GlaxoSmithKline
Grifols Deutschland GmbH
Novartis Deutschland GmbH
Publisher
Springer Science and Business Media LLC
Reference55 articles.
1. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33(5):1165–85.
2. Divo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(2):155–61.
3. Agrawal D, Vohra R, Gupta PP, Sood S. Subclinical peripheral neuropathy in stable middle-aged patients with chronic obstructive pulmonary disease. Singap Med J. 2007;48(10):887–94.
4. Shah S, Salvi S, Kowale A. Peripheral Nerves in Chronic Obstructive Pulmonary Disease: A Review. International Journal of Advanced Physiology and Allied Sciences. 2016;3(1):78–87.
5. Gupta PP, Aggarwal D. Chronic obstructive pulmonary disease and peripheral neuropathy. Lung India. 2006:25.
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献